Chase Investment Counsel Corp Acquires New Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Chase Investment Counsel Corp acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,000 shares of the medical equipment provider’s stock, valued at approximately $1,431,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Parkside Financial Bank & Trust lifted its position in Lantheus by 49.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock valued at $76,000 after purchasing an additional 280 shares during the period. Lingotto Investment Management LLP lifted its position in Lantheus by 61.4% during the fourth quarter. Lingotto Investment Management LLP now owns 89,232 shares of the medical equipment provider’s stock valued at $7,983,000 after purchasing an additional 33,958 shares during the period. Drum Hill Capital LLC bought a new position in Lantheus during the fourth quarter valued at approximately $219,000. Hussman Strategic Advisors Inc. bought a new position in Lantheus in the fourth quarter worth approximately $939,000. Finally, New York State Common Retirement Fund raised its position in Lantheus by 111.5% in the fourth quarter. New York State Common Retirement Fund now owns 197,132 shares of the medical equipment provider’s stock worth $17,635,000 after acquiring an additional 103,931 shares during the period. Institutional investors own 99.06% of the company’s stock.

Lantheus Trading Up 2.5 %

Lantheus stock opened at $93.82 on Friday. Lantheus Holdings, Inc. has a 12-month low of $56.44 and a 12-month high of $126.89. The firm has a 50-day moving average price of $89.80 and a 200-day moving average price of $96.75. The firm has a market capitalization of $6.52 billion, a PE ratio of 15.61 and a beta of 0.44.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. As a group, sell-side analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LNTH has been the topic of several recent research reports. The Goldman Sachs Group initiated coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target on the stock. Truist Financial increased their price objective on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, JMP Securities reiterated a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Lantheus presently has a consensus rating of “Moderate Buy” and a consensus target price of $132.86.

Insider Activity at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.50% of the stock is currently owned by company insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.